Mesoderm Induction via BMP4 and CHIR99021 for Blood Cell Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The signals controlling mesoderm formation and differentiation in human development are not well understood, limiting the efficient induction of blood cells, particularly megakaryocytes and platelets, from human pluripotent stem cells.
Innovation Solution
The method involves contacting pluripotent stem cells with Activin A and BMP4 or CHIR99021 for at least 3 days under serum-free and/or feeder-free conditions to induce CD56-positive and APJ-positive mesoderm cells, which can differentiate into megakaryocytes, platelets, and various blood cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional differentiation protocols are used, then some blood cell differentiation can be achieved, but the differentiation efficiency is insufficient and stable supply cannot be guaranteed
Solution Approach 1:
The patent applies parameter changes by systematically optimizing culture conditions including growth factors (Activin A, BMP4, CHIR99021), cytokines (SCF, TPO, IL-3), and culture time parameters to achieve high-efficiency differentiation. The protocol specifies precise concentrations and timing sequences that transform pluripotent stem cells into blood cells with reliable efficiency
Solution Approach 2:
The patent implements preliminary action through pre-treatment steps where pluripotent stem cells are first differentiated into mesoderm progenitors before final blood cell differentiation. This two-stage preliminary preparation ensures that cells are properly primed for subsequent differentiation, guaranteeing stable and reliable blood cell production
2Ease of manufacture
If differentiation is induced without specific growth factors, then the process is simpler, but differentiation into blood cells is inefficient
Solution Approach 1:
The patent applies universality by using a multi-functional growth factor combination that simultaneously promotes multiple differentiation pathways. The protocol employs Activin A, BMP4, and CHIR99021 together with cytokines like SCF and TPO to achieve both mesoderm formation and blood cell differentiation through a single integrated protocol, maintaining process simplicity while ensuring high productivity
3Reliability
If feeder cells and serum are used in culture, then cell survival is improved, but contamination risk and variability increase
Solution Approach 1:
The patent applies self-service by formulating a complete growth factor and cytokine mixture that provides all necessary survival and differentiation signals without requiring external feeder cells or serum. The protocol specifies precise combinations of defined factors (Activin A, BMP4, CHIR99021, SCF, TPO, IL-3) that enable cells to sustain themselves and differentiate reliably in a contamination-free, controlled environment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the differentiation efficiency of pluripotent stem cells into mesoderm and blood cells, including megakaryocytes and platelets, offering a stable supply for therapeutic applications.
Implementation Method 1
Three humoral factor groups, Nodal/Activin A/TGFβ, WNT3 and BMP4, are known to play an important role in mesoderm formation in mouse development
Data Source
Figure 1
Figure 2A~2E
Figure 3A~3D
AI summary
Provided is a method for inducing mesoderm, comprising a step of bringing pluripotent stem cells into contact with bone morphogenetic protein 4 (BMP4) or CHIR for at least 3 days.